全文获取类型
收费全文 | 310540篇 |
免费 | 19063篇 |
国内免费 | 1569篇 |
专业分类
耳鼻咽喉 | 4284篇 |
儿科学 | 10462篇 |
妇产科学 | 10417篇 |
基础医学 | 46756篇 |
口腔科学 | 7767篇 |
临床医学 | 26264篇 |
内科学 | 58042篇 |
皮肤病学 | 6447篇 |
神经病学 | 21843篇 |
特种医学 | 12215篇 |
外国民族医学 | 56篇 |
外科学 | 47893篇 |
综合类 | 10316篇 |
现状与发展 | 5篇 |
一般理论 | 163篇 |
预防医学 | 20792篇 |
眼科学 | 7314篇 |
药学 | 22408篇 |
20篇 | |
中国医学 | 1757篇 |
肿瘤学 | 15951篇 |
出版年
2021年 | 3032篇 |
2019年 | 2804篇 |
2018年 | 4200篇 |
2017年 | 3170篇 |
2016年 | 3526篇 |
2015年 | 4180篇 |
2014年 | 5455篇 |
2013年 | 7937篇 |
2012年 | 10123篇 |
2011年 | 10647篇 |
2010年 | 6890篇 |
2009年 | 6142篇 |
2008年 | 9473篇 |
2007年 | 10233篇 |
2006年 | 10075篇 |
2005年 | 9676篇 |
2004年 | 9166篇 |
2003年 | 8649篇 |
2002年 | 8172篇 |
2001年 | 13663篇 |
2000年 | 14017篇 |
1999年 | 11757篇 |
1998年 | 3221篇 |
1997年 | 2990篇 |
1996年 | 2816篇 |
1995年 | 2707篇 |
1994年 | 2486篇 |
1992年 | 8418篇 |
1991年 | 8520篇 |
1990年 | 8348篇 |
1989年 | 8134篇 |
1988年 | 7359篇 |
1987年 | 7123篇 |
1986年 | 6757篇 |
1985年 | 6548篇 |
1984年 | 4790篇 |
1983年 | 4143篇 |
1982年 | 2478篇 |
1979年 | 4430篇 |
1978年 | 3232篇 |
1977年 | 2732篇 |
1976年 | 2508篇 |
1975年 | 2840篇 |
1974年 | 3354篇 |
1973年 | 3369篇 |
1972年 | 3122篇 |
1971年 | 2950篇 |
1970年 | 2841篇 |
1969年 | 2583篇 |
1968年 | 2543篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
4.
5.
Clinical and Experimental Medicine - Recently, the use of novel targeted drugs significantly improved the overall response rate (ORR) and survival of patients with relapsed/refractory chronic... 相似文献
6.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献7.
8.
9.
10.